Foresite Capital Management IV’s Syndax Pharmaceuticals SNDX Stock Holding History

Foresite Capital Management IV’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-875,000	Closed	-$16.8M	–	5
2024 Q3	$16.8M	Hold	875,000	–	–	11.01%	3
2024 Q2	$18M	Hold	875,000	–	–	12.07%	3
2024 Q1	$20.8M	Hold	875,000	–	–	10.52%	4
2023 Q4	$18.9M	Hold	875,000	–	–	9.56%	4
2023 Q3	$12.7M	Hold	875,000	–	–	7.06%	7
2023 Q2	$18.3M	Hold	875,000	–	–	9%	7
2023 Q1	$18.5M	Hold	875,000	–	–	9.59%	6
2022 Q4	$22.3M	Buy	875,000 +185,000	+27%	+$4.31M	9.51%	6
2022 Q3	$16.6M	Buy	+690,000	New	+$15.5M	5.33%	6

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Foresite Capital Management IV's SNDX Position: Q4 2024 in Review

Foresite Capital Management IV sold out of Syndax Pharmaceuticals (SNDX) in Q4 2024, closing a stake of 875,000 shares — an estimated $16.8M sold.

Foresite Capital Management IV first reported a position in SNDX in Q3 2022 and held it in 9 quarters. The position peaked at $22.3M in Q4 2022. 215 funds tracked by Wall St. Rank hold SNDX as of Q4 2024.

Foresite Capital Management IV reported no remaining Syndax Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Foresite Capital Management IV sold 875,000 Syndax Pharmaceuticals shares in Q4 2024, an estimated $16.8M.
Foresite Capital Management IV first reported a position in Syndax Pharmaceuticals in Q3 2022 and held it in 9 quarters.
Foresite Capital Management IV's Syndax Pharmaceuticals position peaked at $22.3M in Q4 2022.
215 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2024.

Based on Foresite Capital Management IV's 13F filing for Q4 2024, filed 14 Feb 2025.